Rheumatology and Pulmonary Clinic

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Sjögren's disease3 trials
• ANCA-associated vasculitis1 trial
• Lupus (SLE)1 trial
• Psoriasis1 trial
• Psoriatic arthritis1 trial
• Rheumatoid arthritis1 trial

Phase

• Phase 34 trials
• Phase 22 trials
• Phase 41 trial

Status

• Completed4 trials
• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• Amgen4 trials
• Janssen Research & Development, LLC2 trials
• Kiniksa Pharmaceuticals, Ltd.1 trial

Running trials

• Recruiting

  A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

  NCT06747949· Phase 3· Amgen· Source

• Active, not recruiting

  A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

  NCT06245408· Phase 3· Amgen· Source

• Recruiting

  A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

  NCT06072482· Phase 4· Amgen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• ANCA-associated vasculitis1 recruiting
• Sjögren's disease1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

  NCT06104124· Phase 3· Amgen· Source

• Completed

  Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

  NCT05198310· Phase 2· Kiniksa Pharmaceuticals, Ltd.· Source

• Completed

  Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

  NCT04936308· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

  NCT04882878· Phase 2· Janssen Research & Development, LLC· Source